13F reference period
Q2 2026
Security Snapshot
IRulya Therapeutics Inc. - Common Stock (IRLA) Institutional Ownership
CUSIP: 22053A305
13F Institutional Holders and Ownership History from Q2 2026 to Q3 2026
Institutions Reporting
24
Shares (Excl. Options)
260.08K
Full value: 260,082 · shares · 30 Jun 2026Price
$18.19
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- IRLA on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 260,082
- Total 13F value
- $4,742,378
- Portfolio coverage rank
- 0%
- Share change
- +260,082
- Value change
- +$4,742,378
- Number of holders
- 24
- Shares outstanding
- 10,867,317
- SEC-reported price per share
- $27.87
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- IRLA - IRulya Therapeutics Inc. - Common Stock is tracked under CUSIP 22053A305.
- 24 institutions reported positions in Q2 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- The headline uses Q2 2026 reported holdings.
- Quarter-over-quarter comparison is unavailable because the immediately preceding quarter is missing.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 24 institutions filings for Q2 2026.
Security key
22053A305
13F reference period
Q2 2026
13F holders
24
13D/G owners
6
CIK / CUSIP context first
Open Q2 2026 holders
IRLA full holder history
IRulya Therapeutics Inc. SEC filings
IRulya Therapeutics Inc. company facts
IRulya Therapeutics Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 22053A305:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
IRLA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 8.4% | $26,436,223 | 912,853 | Perceptive Advisors LLC | 06 Oct 2026 | |||
| Foresite Capital Fund VI LP | 6% | $18,883,049 | 652,039 | James B. Tananbaum | 06 Oct 2026 | |||
| Cormorant Asset Management, LP | 10% | $1,863,500 | 108,029 | Cormorant Asset Management, LP | 30 Jun 2026 | |||
| BALYASNY ASSET MANAGEMENT L.P. | 10% | $1,685,308 | 97,699 | BALYASNY ASSET MANAGEMENT L.P. | 30 Jun 2026 | |||
| Ikarian Capital, LLC | 9% | $1,583,360 | 91,789 | Ikarian Capital, LLC | 30 Jun 2026 | |||
| Squadron Capital Management LLC | 5.6% | $951,734 | 55,173 | Squadron Master Fund LP | 28 Jul 2026 |
As of 30 Jun 2026,
24
institutional investors reported holding
shares of
IRulya Therapeutics Inc. - Common Stock (IRLA).
This represents
2.4%
of the company’s total
outstanding shares.
260.08K
Full value: 260,082 · shares · 30 Jun 202610.87M
Full value: 10,867,317 · shares · Stored outstanding share countQuarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
2
Headline period
Q2 2026
Rows shown
1-2 of 2